Due to the unique characteristics of rare diseases, developing medications for them might be difficult. The rarity of a condition makes drug development difficult. Due to a paucity of people, well-designed clinical trials to demonstrate efficacy can be difficult to conduct, and studies substantial enough to determine major hazards are nearly impossible to do. When no other options are available, patients may be ready to risk side effects in exchange for potential benefits, but the benefit-to-harm balance is difficult to quantify and may be unfavourable in some situations. Clinical pharmacology, a translational discipline, is a critical component of drug development, including therapeutic development for rare diseases. Health administrators have financial challenges when it comes to innovative pharmaceuticals, particularly orphan drugs. Individual rare disorders impact a small number of people, yet they collectively affect a significant portion of the population. They require our assistance.
Title : The foundation for rare disease and its role in the european rare disease research landscape
Daniel Scherman, Foundation for Rare Diseases, France
Title : The effect of Eupalinolide B on amyotrophic lateral sclerosis: A case report
Wang Huaixiu, Shanxi Provincial Hospital, China
Title : Progress related in genetic research on kawasaki disease
Jiao Fuyong, Shaanxi Provincial People’s Hospital, China
Title : Covid-19 seems to be Initiated by the heparan-sulfate dysregulation by coronavirus: The use of low-molecular- weight heparin (LMWH) can prevent and treat covid-19 when it Is used in early stages, as a heparan-sulfate-regulating medicine
Fereshteh Sedaghat, Sedaghat Memory Clinic, Iran (Islamic Republic of)
Title : Lumevoq gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Drug recommendation system using a collaborative filtering in machine learning
J. Somasekar, Jain University, India